Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nervgen Pharma Corp (OP: NGENF )

1.790 -0.025 (-1.38%)
Streaming Delayed Price Updated: 3:59 PM EDT, Oct 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,988
Open 1.803
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 1.815
Today's Range 1.780 - 1.805
52wk Range 1.160 - 2.990
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Non-Opioid Revolution: Beacons of Hope in Opioid Crisis and a $50 Million Spin-Off
Via AB Newswire
Life Science Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire

Performance

YTD
-3.24%
-3.24%
1 Month
-10.50%
-10.50%
3 Month
-12.25%
-12.25%
6 Month
+8.48%
+8.48%
1 Year
+29.71%
+29.71%

More News

Read More
Life Science Investor Forum Agenda Announced for June 22nd
From Virtual Investor Conferences
Via GlobeNewswire
NervGen Pharma Announces Leadership Transition
Via Newsfile
Has The Controversy Around Falsified Alzheimer's Research Impacted The Path To Finding The Cure?
Via Benzinga
Encode Ideas, L.P. Announces the Initiation of Research Coverage on NervGen Pharma Corp.
Via Newsfile
NervGen Engages Vorticom Inc. to Provide Media Relations Services
Via Newsfile
Exposures COVID-19
NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve University
From NervGen Pharma Corp.
Via Business Wire
NervGen Pharma Enters into Research Agreement with Sylics to Study NVG-291 in Alzheimer's Disease Models
Via Newsfile
Exposures COVID-19 Product Safety
NervGen Pharma Reports First Quarter 2021 Results
Via Newsfile
Exposures COVID-19 Product Safety
NervGen Pharma Announces Intent to Conduct Groundbreaking Spinal Cord Injury Clinical Trial in Exclusive Partnership With Shirley Ryan AbilityLab, #1-Ranked Hospital in Physical Medicine & Rehabilitation
From NervGen Pharma Corp.
Via Business Wire
NervGen Pharma Announces Closing of Overnight Marketed Equity Offering
Via Newsfile
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021
Via Benzinga
NervGen Pharma Grants Stock Options
Via Newsfile
NervGen Pharma Announces First Subject Dosed in Phase 1 Clinical Trial of NVG-291
Via Newsfile
Exposures COVID-19
NervGen Pharma Announces Pricing of Overnight Marketed Equity Offering
Via Newsfile
Exposures COVID-19
NervGen Pharma Corp. Announces Overnight Marketed Equity Offering
Via Newsfile
Exposures COVID-19
NervGen Pharma Grants Stock Options
Via Newsfile
NervGen Pharma Announces Appointment of Pharma Veteran Dr. Daniel Mikol as Chief Medical Officer
Via Newsfile
Exposures COVID-19 Product Safety
NervGen Pharma Receives Ethics Approval to Initiate Phase 1 Clinical Trial for NVG-291
Via Newsfile
Exposures COVID-19 Product Safety
NervGen Pharma Reports 2020 Year End Results
Via Newsfile
Exposures COVID-19 Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.